NEW YORK (GenomeWeb) – Akonni Biosystems announced today that it has received a $300,000 grant from the National Institutes of Health to finalize development of a rapid, point-of-care tuberculosis assay for use on the company's TruDx 3000 sample-to-answer diagnostic system.

The grant was awarded under the NIH's Commercialization Readiness Pilot program, which is designed to help small businesses transition projects previously funded by the agency into the commercialization stage.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.